GlaxoSmithKline (GSK) has announced FDA approval of raxibacumab anti-toxin as a combination therapy along with antibacterial drugs for the treatment of inhalational anthrax in both adult and pediatric patients with limited treatment options.
Efficacy of the monoclonal anti-toxin medication against inhalational anthrax, caused due to Bacillus anthracis, was established in studies conducted in animal models while the safety profile was demonstrated in healthy adult volunteers.
GlaxoSmithKline infectious diseases senior vice president and head Zhi Hong said, "Raxibacumab is an important part of an ongoing collaboration between GSK and the US government to address a range of public health concerns."
An intravenous administration of a single dose of raxibacumab 40mg/kg throughout a period of two hours and 15 minutes is recommended for adults while the pediatric recommended dose depends on the weight of the children.
